Abstract: Background and purpose: Soluble suppression of tumorigenicity2 (sST2) is a biomarker of myocardial hypertrophy and myocardial fibrosis. This study aimed to investigate the clinical value of sST2 in patients with soft tissue sarcomas. Methods: A cross-sectional survey was conducted in the patients with soft tissue sarcomas treated in Zhongshan Hospital, Fudan University from Jul. 2019 to Aug. 2019. The data were collected, including demographic characteristics, soft tissue sarcoma staging and combined cardiovascular disease. Serum sST2, lactate dehydrogenase (LDH), D-dimer, high-sensitivity C-reactive protein (hs-CRP), cardiac troponin T (cTnT) and N-terminal pro-brain natriuretic peptide (NT-proBNP) were tested in the laboratory before treatment. Data of left ventricular ejection fraction (LVEF) were collected via echocardiography. Results: A total of 64 patients with soft tissue tumor were enrolled, including 29 males and 35 females, average age of 45.9±14.6 years. There were 12 patients with medical history of cardiovascular disease and 2 patients with diabetes mellitus. After natural logarithm transformation, ST2, LDH, D-dimer, NT proBNP, hs-CRP and cTnT were in accordance with normal distribution. Single factor Spearman correlation linear analysis showed that sST2 was highly correlated with LDH, D-dimer, hs-CRP and NT-proBNP (P<0.01). Furthermore, the above independent variables were included in the multiple factor linear regression analysis of sST2. The results showed that sST2 had a high correlation with LDH. Conclusion: In patients with soft tissue sarcomas and relatively normal cardiac function, sST2 is expected to become a new tumor marker.

Key words: Soft tissue sarcomas, ST2, Soluble